Treatment Updates for Small Cell Lung Cancer
Search for other papers by Saiama N. Waqar in
Current site
Google Scholar
PubMed
For more than 40 years, platinum and etoposide induction has been used as first-line treatment for both limited-stage and extensive-stage small cell lung cancer (SCLC), with initially slow progress in the development of novel systemic therapies. However, during the past few years, newer agents have emerged to alter the therapeutic scene in SCLC. These agents include several immunotherapies, selective inhibitors of oncogenic transcription, DLL3-targeting T-cell engagers such as FDA-approved tarlatamab, and antibody–drug conjugates. Results of ongoing studies of these agents may further refine the future treatment of SCLC.
Disclosures: Dr. Waqar has disclosed receiving grant/research support to the institution from AbbVie Inc., Advenchen, AstraZeneca Pharmaceuticals LP, Elevation Oncology, Genentech, Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Regeneron Pharmaceuticals, and Takeda Pharmaceuticals North America, Inc.; and receiving consulting/advisory board fees from AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Daiichi Sankyo Company, Gilead Sciences, Inc., Janssen Pharmaceuticals, and Pfizer Inc.
© 2019-2024 National Comprehensive Cancer Network